Viridian Therapeutics (NASDAQ:VRDN) Trading Up 5.2% – What’s Next?

Viridian Therapeutics, Inc. (NASDAQ:VRDN) was up 5.2% on Thursday . The company traded as high as $15.05 and last traded at $15.2170. Approximately 556,307 shares were traded during trading, a decline of 72% from the average daily volume of 2,015,085 shares. The stock had previously closed at $14.47.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on VRDN shares. Wells Fargo & Company decreased their target price on shares of Viridian Therapeutics from $29.00 to $20.00 and set an “equal weight” rating on the stock in a research note on Tuesday, March 31st. HC Wainwright decreased their target price on shares of Viridian Therapeutics from $34.00 to $22.00 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. Needham & Company LLC decreased their target price on shares of Viridian Therapeutics from $42.00 to $32.00 and set a “buy” rating on the stock in a research note on Monday, March 30th. Wedbush decreased their target price on shares of Viridian Therapeutics from $37.00 to $31.00 and set an “outperform” rating on the stock in a research note on Wednesday. Finally, Truist Financial decreased their target price on shares of Viridian Therapeutics from $41.00 to $40.00 and set a “buy” rating on the stock in a research note on Thursday, January 8th. Thirteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $37.57.

Viridian Therapeutics Trading Up 7.3%

The company has a debt-to-equity ratio of 0.08, a current ratio of 12.65 and a quick ratio of 12.65. The company has a market cap of $1.59 billion, a price-to-earnings ratio of -4.73 and a beta of 1.16. The business’s fifty day moving average price is $27.19 and its 200 day moving average price is $27.73.

Viridian Therapeutics (NASDAQ:VRDN) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.18). Viridian Therapeutics had a negative return on equity of 83.25% and a negative net margin of 483.57%.The business had revenue of $0.13 million during the quarter, compared to the consensus estimate of $15.75 million. Research analysts anticipate that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

Institutional Trading of Viridian Therapeutics

Institutional investors have recently modified their holdings of the business. Aster Capital Management DIFC Ltd bought a new stake in shares of Viridian Therapeutics in the third quarter worth $35,000. ANTIPODES PARTNERS Ltd bought a new stake in shares of Viridian Therapeutics in the fourth quarter worth $36,000. Farther Finance Advisors LLC grew its stake in shares of Viridian Therapeutics by 332.1% in the third quarter. Farther Finance Advisors LLC now owns 1,940 shares of the company’s stock worth $42,000 after purchasing an additional 1,491 shares during the last quarter. Bessemer Group Inc. grew its stake in shares of Viridian Therapeutics by 947.7% in the third quarter. Bessemer Group Inc. now owns 2,085 shares of the company’s stock worth $45,000 after purchasing an additional 1,886 shares during the last quarter. Finally, Larson Financial Group LLC bought a new stake in shares of Viridian Therapeutics in the third quarter worth $52,000.

About Viridian Therapeutics

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.